# Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

> **NCT03452579** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **David Peereboom** · enrollment: 90 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Standard Dose Bevacizumab
- **DRUG:** Low Dose Bevacizumab

## Key facts

- **NCT ID:** NCT03452579
- **Lead sponsor:** David Peereboom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-21
- **Primary completion:** 2020-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452579, "Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03452579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*